All Stories

  1. Baseline Lung Allograft Dysfunction: Definition, Timing, and Implications for Outcomes—an ISHLT Consensus Document
  2. Follow-Up Care after Adult Lung Transplantation: Summary of an Evidence-Based Clinical Practice Guideline for German-Speaking Countries
  3. From “Bridge to Decision” to a “Decision to Bridge”
  4. Lower Limit of Normal of Pulmonary Function to Define Baseline Lung Allograft Dysfunction
  5. An international perspective on allocation rules for combined heart-lung transplantation
  6. Post-Lung Transplantation Care
  7. A European multi-center, randomized controlled trial of Pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation
  8. Point‐of‐Care Testing by Multiplex‐PCR in Different Compartments in Suspected Lower Respiratory Tract Infection After Lung Transplantation—Results of a Prospective Study
  9. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
  10. Lung transplantation for COPD/pulmonary emphysema
  11. How Well Preventive Treatment Works to Stop COVID-19 in Lung Transplant Patients
  12. The antiviral drug presatovir for respiratory syncytial virus infection after lung transplant
  13. Gamma-glutamyltransferase is a strong predictor of secondary sclerosing cholangitis after lung transplantation for COVID-19 ARDS
  14. Eine Querschnittsuntersuchung zur Qualität der Sauerstofftherapie in drei deutschen Krankenhäusern
  15. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study
  16. Comparative analysis of fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis
  17. Value of functional lung MRI in long term patient care after lung transplantation.
  18. Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study
  19. Sauerstoff in der Akuttherapie
  20. Eine Querschnittsuntersuchung zur Qualität der Sauerstofftherapie in drei deutschen Krankenhäusern
  21. Correspondence
  22. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions
  23. Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation
  24. Lung transplant and severe coronary artery disease: results from a single-centre experience
  25. Better survival in SARS-2 infected patients after lung transplantation with an antibody cocktail
  26. Lung transplantation in HIV-positive patients: a European retrospective cohort study
  27. Chest Infections After Lung Transplantation
  28. Graphic narrative based informed consent for bronchoscopy improves satisfaction in patients after lung-transplantation: A randomized controlled trial
  29. Five-year Outcome of an Early Everolimus-based Quadruple Immunosuppression in Lung Transplant Recipients: Follow-up of the 4EVERLUNG Study
  30. Kidney injury after lung transplantation: Long-term mortality predicted by post-operative day-7 serum creatinine and few clinical factors
  31. Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis
  32. Nutzen und Risiken der Behandlung mit Sauerstoff
  33. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients
  34. Stille Hypoxie bei COVID-19: Eine Fallserie
  35. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction—A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial
  36. German S3 Guideline: Oxygen Therapy in the Acute Care of Adult Patients
  37. Silent Hypoxia in COVID-19: A Case Series
  38. Lung Transplantation for Acute Respiratory Distress Syndrome
  39. Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies
  40. Quality of domiciliary oxygen therapy in adults with chronic respiratory diseases
  41. Sauerstoff in der Akuttherapie beim Erwachsenen
  42. COVID-19 in lung transplant recipients—Risk prediction and outcomes
  43. Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation: Results of the prospective DBATE‐IT * study
  44. Sauerstofftherapie in der Akut- und Notfallmedizin
  45. Clinical decision making is improved by rapid multiplex-PCR in suspected lower respiratory tract infection after lung transplantation in a prospective cohort study
  46. S3-Leitlinie Sauerstoff in der Akuttherapie beim Erwachsenen
  47. The Transplant Evaluation Rating Scale Predicts Clinical Outcomes 1 Year After Lung Transplantation: A Prospective Longitudinal Study
  48. Video Consultation During the COVID-19 Pandemic: A Single Center's Experience with Lung Transplant Recipients
  49. Oxygen Treatment in COVID-19
  50. Pulmonary Fibroelastotic Remodelling Revisited
  51. Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy
  52. Delayed non-myeloablative irradiation to induce long-term allograft acceptance in a large animal lung transplantation model
  53. Characteristics and clinical implications of pleural effusions after lung transplantation: A retrospective analysis of 195 thoracocenteses in 113 patients
  54. Sauerstofftherapie bei Kandidaten zur Lungentransplantation − eine monozentrische retrospektive Analyse von 807 Patienten
  55. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity
  56. Impact of unilateral diaphragm elevation on postoperative outcomes in bilateral lung transplantation – a retrospective single‐center study
  57. Lung transplantation for sarcoidosis: outcome and prognostic factors
  58. Viral load-guided immunosuppression after lung transplantation (VIGILung)—study protocol for a randomized controlled trial
  59. A Before-and-After Study of Evidence-Based Recommendations for On-Call Bronchoscopy
  60. Risikoabschätzung bei Patienten mit chronischen Atemwegs- und Lungenerkrankungen im Rahmen der SARS-CoV-2-Pandemie
  61. Viral load Guided Immunosuppression after Lung Transplantation (VIGILung) – study protocol for a randomized controlled trial
  62. Impact of COVID-19 on Lung Transplant Activity in Germany—A Cross-Sectional Survey
  63. Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation
  64. Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients
  65. Impact of donor lung quality on post‐transplant recipient outcome in the Lung Allocation Score era in Eurotransplant – a historical prospective study
  66. Adherence is associated with a favorable outcome after lung transplantation
  67. Saving those who can't wait
  68. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infectio...
  69. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation
  70. Community-acquired respiratory viruses
  71. MRI‐derived regional flow‐volume loop parameters detect early‐stage chronic lung allograft dysfunction
  72. Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome―A consensus report from the Pulmonary Council of the ISHLT
  73. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT
  74. Lungentransplantation
  75. Oxygen Therapy for Isolated Exercise-Induced Hypoxemia Should Be Prescribed With Caution
  76. Need for and Outcomes of Intraoperative Extracorporeal Circulatory Support in Lung Transplantation for Pulmonary Fibrosis
  77. Predicted Total Lung Capacity Ratio between Donors and Recipients Does Not Predict Outcomes in Non-Volume Reduced Lung Transplantation
  78. Initial immunosuppression and managing rejection
  79. Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation
  80. Transplantation of donor lungs with pulmonary embolism - a retrospective study
  81. Risk factors and outcomes of vocal cord paralysis after lung transplantation - a retrospective cohort study
  82. Lungentransplantation bei Lungenkarzinom
  83. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years
  84. O 2 saturation target of 96–100% should be abandoned
  85. Wartelistenführung und Organvermittlung zur Lungentransplantation 2018 – Aktuelles für den Pneumologen
  86. Lobe-wise assessment of lung volume and density distribution in lung transplant patients and value for early detection of bronchiolitis obliterans syndrome
  87. Detection of chronic lung allograft dysfunction using ventilation-weighted Fourier decomposition MRI
  88. Management of Spontaneous Pneumothorax and Post-Interventional Pneumothorax: German S3 Guideline
  89. Management of Spontaneous Pneumothorax and Postinterventional Pneumothorax: German S3-Guideline
  90. Heart re-transplantation in Eurotransplant
  91. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study
  92. The burden of sinus disease in cystic fibrosis lung transplant recipients
  93. Breath volatile organic compounds of lung transplant recipients with and without chronic lung allograft dysfunction
  94. The liver-first approach for combined lung and liver transplantation
  95. The Transplant Evaluation Rating Scale (TERS): A Tool for the Psychosocial Evaluation of Lung Transplant Candidates
  96. Endobronchial Ultrasound in Suspected Non-Malignant Mediastinal Lymphadenopathy
  97. Lung allocation score: the Eurotransplant model versus the revised US model - a cross-sectional study
  98. Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis
  99. 3-and 5-Year Results of Lung Preservation with the Organ Care System: Insights from a Single-Center Experience
  100. A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients
  101. Benefits of Early Everolimus-Based Quadruple Immunosuppression Early After Lung Transplantation - Results of 4EVERLUNG, a Prospective Randomized Multicenter Trial
  102. Lung Transplantation for Scleroderma Lung Disease: Indications, Survival and Prognosis
  103. Vocal Cord Paralysis After Lung Transplantation Does Not Influence Early Outcome
  104. Community-Acquired Respiratory Viruses
  105. Technique and Outcomes of Less Invasive Lung Retransplantation
  106. Self-reported non-adherence to immunosuppressive medication in adult lung transplant recipients-A single-center cross-sectional study
  107. Infection transmission among lung transplant couples
  108. Single lung transplantation from a donor 8 months after double lung transplantation
  109. Lung transplantation after allogeneic stem cell transplantation: a pan-European experience
  110. Recent advances in extracorporeal life support as a bridge to lung transplantation
  111. DNA-based testing in lung transplant recipients with suspected non-viral lower respiratory tract infection: A prospective observational study
  112. Transplanting HCV-Infected Kidneys into Uninfected Recipients
  113. Breath VOC patterns of lung transplant recipients with and without chronic lung allograft dysfunction (CLAD)
  114. CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival
  115. Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation
  116. In Reply
  117. Lung allocation
  118. Splenocyte Infusion and Whole-Body Irradiation for Induction of Peripheral Tolerance in Porcine Lung Transplantation: Modifications of the Preconditioning Regime for Improved Clinical Feasibility
  119. Cellular analysis in bronchoalveolar lavage: inherent limitations of current standard procedure
  120. Biodegradable stent for vanishing bronchus syndrome after lung transplantation
  121. Response
  122. “White-Out” After Lung Transplantation: A Multicenter Cohort Description of Late Acute Graft Failure
  123. Early Natural Killer Frequencies and Chronic Lung Allograft Dysfunction Two Years After Lung Transplantation
  124. Risk Factors for Intraoperative Extracorporeal Circulatory Support in Patients Undergoing Lung Transplantation for Pulmonary Fibrosis
  125. Technique and Outcomes of Less Invasive Lung Retransplantation
  126. Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score
  127. Irradiation before and donor splenocyte infusion immediately after transplantation induce tolerance to lung, but not heart allografts in miniature swine
  128. Mid-term results of bilateral lung transplant with postoperatively extended intraoperative extracorporeal membrane oxygenation for severe pulmonary hypertension†
  129. Repeated human leukocyte antigen mismatches in lung re-transplantation
  130. Response
  131. Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation
  132. An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe
  133. Phenotyping Chronic Lung Allograft Dysfunction Using Body Plethysmography and Computed Tomography
  134. Lung transplantation in the spotlight: Reasons for high-cost procedures
  135. Dichotomy in pulmonary graft- versus -host disease evident among allogeneic stem-cell transplant recipients undergoing lung transplantation: TABLE 1
  136. The burden of sinus disease in CF candidates for lung transplantation
  137. CF sinus disease after lung transplantation
  138. Exhaled nitric oxide: A biomarker for chronic lung allograft dysfunction?
  139. Risk of post-transplantation diabetes mellitus (PTDM) with different calcineurin inhibitors
  140. ICU Care Before and After Lung Transplantation
  141. Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation
  142. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial
  143. Lung transplantation for non-cystic fibrosis bronchiectasis
  144. ‘Unacceptable’ Human Leukocyte Antigens in Lung Re-Transplantation
  145. Correlation New UNOS LAS and ET LAS
  146. Early Donor Specific Antibodies Correlate with a Distinct Peripheral Cellular Immune Phenotype after Lung Transplantation
  147. Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database
  148. Heart-Lung Transplantation for Congenital Heart Disease: A 25 Years Single Center Experience
  149. IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplantation
  150. Lung First vs. Liver First Sequence for Combined Lung and Liver Transplantation
  151. Outcomes in Lung Transplantation Following Allogeneic Stem-Cell Transplantation: A Pan-European Experience
  152. Risk Factors and Impact of Bronchial Stenoses after Lung Transplantation: Ten Year Single Center Experience with over 1,100 Patients
  153. Topical Nasal Anesthesia in Flexible Bronchoscopy – A Cross-Over Comparison between Two Devices
  154. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
  155. Prolonged Mechanical Ventilation After Lung Transplantation-A Single-Center Study
  156. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients
  157. BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma
  158. Five-year experience with intraoperative extracorporeal membrane oxygenation in lung transplantation: Indications and midterm results
  159. Allokationssysteme in der Transplantationsmedizin
  160. Chronische Abstoßung
  161. IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation
  162. Molecular Profiling in Lung Biopsies of Human Pulmonary Allografts to Predict Chronic Lung Allograft Dysfunction
  163. Epithelial and Erythrocyte Microvesicles From Bronchoalveolar Lavage Fluid Are Elevated and Associated With Outcome in Chronic Lung Allograft Dysfunction
  164. Percutaneous dilatational tracheostomy (PDT) in trauma patients: a safe procedure
  165. Survival and spirometry outcomes after lung transplantation from donors aged 70 years and older
  166. Local Anesthetics delivered through Pleural Drainages improve Pain and Lung Function after Cardiac Surgery
  167. The impact of long-term air pollution and traffic on outcome after lung transplantation in Europe
  168. Return to work after lung-transplantation – A cross-sectional single-center study
  169. Lung transplantation for Non- Cystic fibrosis bronchiectasis: A single centre retrospective analysis of 34 patients
  170. Lung transplantation following endoscopic lung volume reduction
  171. Lung Preservation With Perfadex or Celsior in Clinical Transplantation
  172. Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
  173. Chronic Lung Allograft Dysfunction: Oxygen-enhanced T1-Mapping MR Imaging of the Lung
  174. Gastrointestinal Endoscopy Is Safe in Patients Before and After Lung or Heart Transplantation
  175. The unusual journey of a tooth. Found but not lost?
  176. When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient
  177. Retrogradein situversus antegrade pulmonary preservation in clinical lung transplantation: a single-centre experience
  178. An Innovative Everolimus-Based Quadruple Low Immunosuppressive Regimen Compared to Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design
  179. Early Donor Specific Antibodies After Lung Transplantation Lead to an Increase of CD56+CD16+ NK Cells in Peripheral Blood
  180. Extracorporeal Membrane Oxygenation for Concomitant Coronary Artery Bypass Grafting and Lung Transplantation
  181. Human Intravenous Immunoglobulins With Rituximab vs. Therapeutic Plasma Exchange With Rituximab for Pre-Emptive Treatment of Early Donors Specific Antibodies After Lung Transplantation: Preliminary Result
  182. Intra-Operative Indication Extracorporeal Membrane Oxygenation for Cardiopulmonary Support During Lung Transplantation: Risk Factors and Mid-Term Results
  183. Intraoperative Cardiopulmonary Support With Extracorporeal Membrane Oxygenation in Lung Transplantation: Favorable Outcomes in High Risk Patients
  184. Perioperative ECMO Use in Lung Transplantation for Severe Pulmonary Hypertension
  185. Survival and Spirometry Outcomes Following Lung Transplantation From Donors >70 Years - Extended Criteria Coming of Age
  186. The Era Effect on Pediatric Lung Transplantation Outcomes
  187. Employment after Lung Transplantation
  188. Postoperative Weight Gain during the First Year after Kidney, Liver, Heart, and Lung Transplant: A Prospective Study
  189. Lung Transplantation for Severe Pulmonary Hypertension—Awake Extracorporeal Membrane Oxygenation for Postoperative Left Ventricular Remodelling
  190. Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation
  191. Lung Transplantation after Endoscopic Lung Volume Reduction
  192. Cardiac Mass and Function Decrease in Bronchiolitis Obliterans Syndrome after Lung Transplantation: Relationship to Physical Activity?
  193. Early donor-specific antibodies in lung transplantation: Risk factors and impact on survival
  194. Lungentransplantation
  195. Lung transplantation for interstitial lung diseases
  196. Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation
  197. C1-Esterase-Inhibitor for Primary Graft Dysfunction in Lung Transplantation
  198. Introduction of the Lung Allocation Score in Germany
  199. Lung transplantation for cystic fibrosis
  200. Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 procedures
  201. Significance of new lung infiltrates in outpatients after lung and heart-lung transplantation
  202. Bronchial Wall Measurements in Patients after Lung Transplantation: Evaluation of the Diagnostic Value for the Diagnosis of Bronchiolitis Obliterans Syndrome
  203. Developing a Score of Early Postoperative Regulatory T Cell Frequency To Predict Bronchiolitis Obliterans Syndrome-Free Survival at Two Years After Lung Transplantation
  204. Donor Oxygenation Has No Impact on Postoperative Outcome After Lung Transplantation
  205. Is Routine Screening for Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients Worthwhile?
  206. Postoperative Donor Specific Anti-HLA Antibodies in Lung Transplantation: Risk Factors and Impact on Mid-Term Patient and Graft Outcomes
  207. Pre-Emptive Treatment of Donor Specific Anti-HLA Antibodies in Lung Transplantation With Plasmapheresis
  208. The ‘Blood Transfusion Effect’ in Lung Transplantation - Striking Evidence for an Old Hypothesis in an Unlikely Setting
  209. The Impact of Air Pollution on Outcome After Lung Transplantation in Europe
  210. Telemedizinische Erfassung der Lungenfunktion bei Patienten nach Lungentransplantation
  211. Conventional vs. Tablet Computer-Based Patient Education following Lung Transplantation – A Randomized Controlled Trial
  212. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients
  213. Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients
  214. A relevant experimental model for human bronchiolitis obliterans syndrome
  215. Extended criteria donor lungs and clinical outcome: Results of an alternative allocation algorithm
  216. Tissue concentration of paraquat on day 32 after intoxication and failed bridge to transplantation by extracorporeal membrane oxygenation therapy
  217. Health-Related Quality of Life After Solid Organ Transplantation
  218. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients: Table 1–
  219. Lungentransplantation
  220. Lung Transplantation for Interstitial Lung Diseases and Pulmonary Hypertension
  221. Low Exercise Tolerance Correlates With Reduced Inspiratory Capacity and Respiratory Muscle Function in Recipients With Advanced Chronic Lung Allograft Dysfunction
  222. Bronchiolitis Obliterans Syndrome-Free Survival after Two Years in Patients with Higher Frequencies of Regulatory T Cells Early after Lung Transplantation
  223. C1-Esterase-Inhibitor Counteracts Severe Primary Graft Dysfunction in Lung Transplantation
  224. 1240 CHRONIC HEPATITIS E IN LUNG TRANSPLANT RECIPIENTS
  225. Comparison of an Innovative Everolimus-Containing Quadruple Immunosuppressive Regimen Versus a Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design
  226. Impact of Lung Allocation Score on Transplantation Activity and Outcomes – Initial German Experience
  227. Increasing Creatine Phosphokinase and Myglobine Levels Predict the Development of Acute Renal Failure Immediately after Combined Heart-Lung Transplantation
  228. Lung Transplantation for Pulmonary Lymphangioleiomyomatosis: Single-Centre Experience
  229. Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients
  230. Biodegradable stents after lung transplantation
  231. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience
  232. Indikationen und Ergebnisse der Lungentransplantation bei idiopathischer Lungenfibrose
  233. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
  234. The influence of clinical course after lung transplantation on rehabilitation success
  235. Lung transplantation on cardiopulmonary support: Venoarterial extracorporeal membrane oxygenation outperformed cardiopulmonary bypass
  236. <I>Mycobacterium intracellulare</I> bacteraemia in a double lung transplant patient [Correspondence]
  237. Renal function and survival in 200 patients undergoing ECMO therapy
  238. 12 Years of Experience in Combined Lung and Liver Transplantation - Changes Over Time and Long Term Outcome
  239. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients
  240. Preoperative Irradiation and Donor Splenocyte Infusion Induce Tolerance in Lung, but not Heart Allografts in a Minipig Model - Role of Passenger Leukocytes
  241. Regulatory T Cells Correlate with Percent Predicted FEV1 after Lung Transplantation
  242. The Problem after Lung Transplantation for Idiopathic Pulmonary Artery Hypertension Is not the Right Ventricle - Awake ECMO for LV Remodelling
  243. The Problem after Lung Transplantation for Idiopathic Pulmonary Artery Hypertension Is not the Right Ventricle - Awake ECMO for LV Remodelling
  244. Treatment of Hepatitis E in Solid Organ Transplant Recipients
  245. Warm Perfusion of the Donor Lung for Preservation Might Have Positive Immunomodulatory Effects after Transplantation
  246. HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation
  247. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients
  248. The lung transplant patient in the ICU
  249. Lung transplantation for pulmonary hypertension
  250. Renal Comorbidity After Solid Organ and Stem Cell Transplantation
  251. Viremia after Lung Transplant: A Cohort Study on Risk Factors and Symptoms Associated with Detection of Epstein-Barr Virus
  252. Multicentre European study for the treatment of advanced emphysema with bronchial valves
  253. Lungentransplantation
  254. Outcome of critically ill lung transplant candidates on invasive respiratory support
  255. 143 A Web-Based Pilot Study of Judgment of the Transplant Benefit by Transplant Experts in Comparison to the Lung Allocation Score: The Eurotransplant Experience
  256. Extracorporeal Membrane Oxygenation in Awake Patients as Bridge to Lung Transplantation
  257. 327 Good Lungs for Bad Recipients and Bad Lungs for Good Recipients – Follow Up on Eurotransplant Rescue Offers
  258. 277 Lung Transplant Surgery on Cardiocirculatory Support: Extracorporeal Membrane Oxygenation Outcompetes Cardiopulmonary Bypass
  259. 218 Not the Right, but the Left Ventricle Causes the Problem after Lung Transplantation for Pulmonary Artery Hypertension – Awake ECMO for Postoperative LV Remodelling
  260. 622 Preoperative Irradiation and Donor Splenocyte Infusion Induce Tolerance in Lung, but Not Heart Allografts in a Minipig Model – Role of Passenger Leukocytes
  261. 63 Regulatory T Cells Correlate with Percent Predicted FEV1 after Lung Transplantation
  262. Spirometric Obstructive Lung Function Pattern Early After Lung Transplantation
  263. Improved Packing and Routing of Vehicles with Compartments
  264. Lung function early after lung transplantation is correlated with the frequency of regulatory T cells
  265. Rare indications for lung transplantation
  266. Graft-Protective Effects of the HMG-CoA Reductase Inhibitor Pravastatin After Lung Transplantation— A Propensity Score Analysis With 23 Years of Follow-Up
  267. Proteomic Bronchiolitis Obliterans Syndrome Risk Monitoring in Lung Transplant Recipients
  268. Transplantationsassoziierte Pathologie der Lunge
  269. Plexiform Lesions in Pulmonary Arterial Hypertension
  270. Single-Centre Experience with Oral Ribavirin in Lung Transplant Recipients with Paramyxovirus Infections
  271. 169 Clinical Significance of Cytomegalovirus (CMV) Detected by RT-PCR in Bronchoalveolar-Lavage Fluid of Stable Lung Transplant Recipients
  272. 555 FoxP3 Positive Treg Correlate with Percent Predicted FEV1 Early after Lung Transplantation
  273. 444 Pulmonary Retransplantation: A Single Center Experience
  274. Therapeutic Drug Monitoring of Mycophenolic Acid After Lung Transplantation—Is It Clinically Relevant?
  275. Incidence and outcome of abdominal surgical interventions following lung transplantation—a single center experience
  276. RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
  277. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series
  278. Obliterative Airway Remodeling
  279. Pulmonary retransplantation in paediatric patients: a justified therapeutic option? A single-centre experience
  280. Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant
  281. Endoscopic Indicators for Obstructive Airway Complications After Lung Transplantation
  282. Incidence and impact of herpes simplex and cytomegalovirus detection in the respiratory tract after lung transplantation
  283. Self-Expanding Metallic Stent Placement with Laryngeal Mask in Lung Transplant Recipients
  284. Use of telehealth technology for home spirometry after lung transplantation: a randomized controlled trial
  285. Catheter Fragmentation and Local Lysis in Two Lung Transplant Patients with Pulmonary Embolism
  286. Lungentransplantation bei Lungenemphysem – Wer? Wann? Wie?
  287. Biopsy‐Diagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues
  288. Chronische respiratorische Insuffizienz: Rolle der Lungentransplantation
  289. Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation
  290. Health-Related Quality of Life in Long-Term Survivors After Heart and Lung Transplantation: A Prospective Cohort Study
  291. Obliterative airway remodelling in transplanted and non-transplanted lungs
  292. Initial Safety Evaluation Of A European Multicenter, Single Blinded And Randomized Study For The Treatment Of Advanced Emphysema With Bronchial Valves
  293. Non- Lobar Atelectasis Approach For The Treatment Of Advanced Emphysema With Bronchial Valves In A European Multicenter, Single Blinded And Randomized Study
  294. Vehicle routing with compartments: applications, modelling and heuristics
  295. Endoskopische Palliation bei Ösophagus- und Bronchialkarzinomen
  296. 423: Avoiding Mechanical Ventilation during Extracorporeal Membrane Oxygenation before Lung Transplantation Decreases Postoperative Mortality
  297. 36: Efficacy of Oral Ribavirin in Lung Transplant Recipients with Paramyxoviral Infection
  298. 160: Evaluation of the Lung Allocation Score in High Urgent and Urgent Lung Transplant Candidates in Eurotransplant
  299. 27: Lung Transplantation as Treatment for Pulmonary Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience
  300. 31: Outcome of Lung Transplant Candidates on Mechanical Ventilation or Extracorporal Support
  301. 362: PTLD after Lung Transplantation – Influence of CMV Prophylaxis on Incidence – Multicentre Centre Analysis and Review of the Literature
  302. 41: Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV)
  303. 348: Splenocyte Infusion and Low Dose Irradiation Induce Peripheral Tolerance in Porcine Lung Transplantation – Modifications of the Protocol for Improved Clinical Feasibility
  304. Vibration response imaging (VRI) in lung transplant recipients
  305. Significance of patient self-monitoring for long-term outcomes after lung transplantation
  306. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation
  307. Lungentransplantation bei Mukoviszidose – ein Positionspapier
  308. Effect of Adherence to Home Spirometry on Bronchiolitis Obliterans and Graft Survival After Lung Transplantation
  309. Community-Acquired Respiratory Viral Infections in Lung Transplant Recipients: A Single Season Cohort Study
  310. Correlation of Donor Leukocyte Chimerism With Pulmonary Allograft Survival After Immunosuppressive Drug Withdrawal in a Porcine Model
  311. Are metallic stents really safe? A long-term analysis in lung transplant recipients
  312. Detection of Epstein–Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation
  313. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis
  314. Lungentransplantation
  315. Bridge to Thoracic Organ Transplantation in Patients with Pulmonary Arterial Hypertension Using a Pumpless Lung Assist Device
  316. Lung and Heart–Lung Transplantation in Children and Adolescents: A Long-term Single-center Experience
  317. Symptom experience after solid organ transplantation
  318. Intentional ABO‐Incompatible Lung Transplantation
  319. Review: Update on lung transplantation
  320. Komplikationen nach Lungentransplantation
  321. Komplikationen nach Lungentransplantation
  322. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases
  323. 87: Advanced Chronic Kidney Disease Early after Lung Transplantation Predicts Worse Outcome
  324. 449: Celsior for Graft Preservation in Clinical Lung Transplantation
  325. 56: Clinical Indicators for Steroid Response in Biopsy Proven Acute Allograft Rejection in Lung Transplant Recipients
  326. 38: Comparison of Voriconazole Versus a Combination of Voriconazole and Caspofungin as Primary Therapy for Suspected Invasive Aspergillosis in Lung Transplant Recipients
  327. 384: ECLA vs. ECMO — Impact of Different Extracorporeal Life Support Systems as a Bridge to Lung Transplantation – A Single Center Retrospective Analysis
  328. 26: Effect of Non-Adherence to Home Spirometry on Graft Survival and Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation
  329. 36: Epstein-Barr Virus Reactivation Is Associated with Mild Clinical Symptoms during the Posttransplant Period of Lung Transplant Recipients
  330. 401: Everolimus Versus Mycophenolatemofetil in De Novo Immunosuppression after Lung Transplantation – Interims Analysis of a Prospective, Randomized, Clinical Trial
  331. 411: Home Based Exercise Training in Lung and Heart Transplant Recipients – Effects on Maximum and Endurance Exercise Capacity
  332. 65: Influence of Ischemic Time on Survival and Chronic Rejection in Lung Transplantation
  333. 487: Longitudinal Assessment of Non-Adherence with Lung Function Monitoring after Lung Transplantation
  334. 66: Lung Transplantation in Patients on Invasive Ventilation and Extracorporeal Membrane Oxygenation
  335. 380: Use of Cardiopulmonary Bypass in Patients Undergoing Minimally Invasive Bilateral Lung Transplantation
  336. Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation
  337. Interventional Lung Assist: A New Concept of Protective Ventilation in Bridge to Lung Transplantation
  338. Symptom experience after lung transplantation: impact on quality of life and adherence
  339. Lungentransplantation
  340. Bridge to Lung Transplantation With the Extracorporeal Membrane Ventilator Novalung in the Veno-Venous Mode: The Initial Hannover Experience
  341. Post-operative Nosocomial Infections After Lung and Heart Transplantation
  342. 470: Daclizumab induction therapy in clinical lung transplantation – a prospective, double-blinded, randomized trial
  343. 134: Impact of airway colonization with gram-negative bacteria on developement of bronchiolitis-obliterans-syndrome in lung transplant recipients with cystic fibrosis
  344. 450: Invasive aspergillosis in lung transplant recipients: The impact of pretransplant colonization
  345. 313: Minimally invasive lung transplantation in more than 145 patients with emphysema: It should be the standard approach
  346. 182: Time course of physical reconditioning during 3 years after lung transplantation – effects of exercise rehabilitation
  347. Clinical relevance of and risk factors for HSV-related tracheobronchitis or pneumonia: results of an outbreak investigation
  348. Long-term outcome after pulmonary retransplantation
  349. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung
  350. 216
  351. 178
  352. 375
  353. 392
  354. Applications of Racing Algorithms: An Industrial Perspective
  355. Empirical Analysis of Locality, Heritability and Heuristic Bias in Evolutionary Algorithms: A Case Study for the Multidimensional Knapsack Problem
  356. Health-Related Quality of Life in Two Hundred-Eighty Lung Transplant Recipients
  357. Tissue Remodeling in a Bioartifical Fibromuscular Patch Following Transplantation in a Human
  358. Surveillance invasiver Fadenpilzmykosen in lungentransplantierten Patienten: Effekt antimykotischer Prophylaxe mit Itraconazol und Voriconazol. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis wi...
  359. Lungentransplantation
  360. Daily routine patient-controlled lung function testing using electronic spirometry is essential for long-term outcome following lung transplantation
  361. Health-related quality of life in 280 transplant recipients
  362. Pulmonary retransplantation for patients with the bronchiolitis-obliterans-syndrome - a single center experience
  363. Reduced size lung transplantation for fibrosis and cystic fibrosis-one year follow up
  364. Risk factors for perioperative mortality and nosocomial infections in lung transplantation
  365. Successful bridge to clinical lung transplantation using the pumpless extracorporeal lung assist device NovaLung® in patients with severe ventilation-refractory hypercapnia
  366. Lungentransplantation
  367. Evolutionary Algorithms for the Satisfiability Problem
  368. In vitro excision of adeno-associated virus DNA from recombinant plasmids: isolation of an enzyme fraction from HeLa cells that cleaves DNA at poly(G) sequences.